We bring Yoga- and Mindfulness services to companies in Oslo and Stavanger. A lot of prestigious companies are already enjoying our services, and our instructors are top-of-the-shelf and super-motivated! The Bedriftsyoga- team truly believe that ALL companies are benefited from having Yoga and Mindfulness at their workplace! It's a win-win for the employee, company and society ;D

People find going to the optician frustrating and it is something they tend to delay as long as possible. Pain points include complicated, non-transparent pricing, lack of understanding about lenses and the options available, and insecurity when choosing glasses. Our mission is to remove these pain points and provide a more relevant modern alternative to the traditional optician. Our vertical concept allows us to offer high-quality designer eyewear at affordable prices - enabling people to build a collection of eyewear to meet the needs of their individual lifestyles. We are currently generating 14 million Nok in sales per year through our 5 Kaibosh stores (Oslo, Bergen, Copenhagen, Frederiksberg & Aarhus), e-commerce operation, and wholesale distribution channels.

Grasp Your Future Our goal is to increase effectiveness and efficiency of medical treatments through person-centered care and improved clinician-patient communication. Grasp concept One-minute video presenting how Grasp works. Grasp Tracker A patented, CE-marked, and approved medical device. You simply squeeze the device when tracking your symptoms, behavior, and events. Grasp User app Through the user app, the doctor is connected to the patient´s everyday life in real-time: at home, at work, or while engaging in activities. Grasp Clinical solution The doctor can remotely and easily adjust the treatment, modify medical plans or give tailored behavioral feedback to increase the function of the patient

Elife E-bikesWe design and import components directly from industries (Germany etc.) and handmake e-bikes in Norway. This is the 3 rd year for us, we have our shop in Oslo and started our focus on developing&producing. We have distributors in Norway and Iceland. Our advantage is that all our competitors can be potential partners. In 2018, we have handmade the lightest three-seater "e-bike-car" in the world - iCloud. It allows 2 People to pedal at the same time. It protects you from bad weather & has a 150L trunk. Its battery range is 200km.

The future of the internet is 3D, and people will increasingly create and express themselves in 3D. Sloyd is using automation to make the creation of 3D faster and more accessible and to make 3D rendering more efficient. We are building a simple-to-use WebApp to quickly generate 3D assets and a software development kit for performance-efficient runtime creation in video games and virtual worlds. Sloyd combines procedural generation techniques, machine learning, and a commitment to real-time optimization to provide the best 3D automation tools. Sloyd is a remote-first company and employees can work from home, a shared-space hub, or from the main office in Oslo. We don’t care where you come from, we only care about your passion and creativity.

Monio AS (org. nr. 913 978 617) er et heleid datterselskap av SpareBank 1 SR-Bank ASA (org. nr. 937 895 321). Monio AS formidler lån til små og mellomstore bedrifter og er regulert av Finanstilsynet med tillatelse til å drive virksomhet som betalingsforetak og er registrert som låneformidler. Som lånformidler er Monio ikke en part i låneavtalen mellom långiver og låntaker.

Biozep is discovering and developing first-in-class drug products for the treatment of severe eye diseases which can lead to vision loss and where it is a high unmet medical need. Biozep has discovered novel drug substances based on bioactive lipids which modulate central pathways involved in the pathogenesis of eye diseases. Targets and biomarkers are identified based on a system biology approach combined with in-depth knowledge about bioactive lipids, their endogenous synthesis and mechanisms of action. Biozep has made a prototype drug product based on our lead compound for topical administration and the product will be tested in animal models in 2018. Our goal is to start clinical studies in 2020. Biozep is a company depending on both internal and external resources. Biozep has established its own laboratory in Oslo in order to do synthesis, purification, quality control and chemical development in-house. The biological testing of the drug substances is performed in collaboration with carefully selected contract research organizations both in Europe and the USA. In order to reach the market as fast as possible and to reduce risk, Biozep will seek strategic partnerships early in the drug development phase. Biozep seeks partners with complementary competence and with resources to conduct clinical trials and with market access. We are already in dialogue with potential partners and hope to sign an agreement in 2018-19.

Yetz is a new distribution platform for product lines such as insurance, electricity, telecom, and finance. At launch, we will offer both insurance and power. We utilize strong incentives towards our customers and partners to share the concept, by giving them an affiliate commission. Monthly payment is based on the turnover of customers they have referred. Two fully owned sister companies Yetz Strøm og Yetz Forsikring.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

MER er et norsk musikkselskap og artistrepresentant. Vår visjon er å bli bransjens beste på å kvalitetssikre, utvikle, fasiliteter og forvalte alle aspekter ved våre klienters karriere og virke. Selskapet har kompetanse og relevant erfaring i å tilby tjenester som management, promo, merkevarebygging og labefunksjoner. MER har de siste årene blitt et internasjonalt selskap med aktivitet over hele verden. Vår største klient, Alan Walker er i dag en av verdens største EDM-artister hvilket gir store muligheter for å bli kjent med en digital musikkverden.

Bookd AS ble etablert i 2021 og jobber med å forenkle bookingprosesser i underholdningsbransjen. Vårt fokus er å tilby underholdning på en enkel og intuitiv måte til bedrifts- og privatarrangementer. Vi har utviklet en app (iOS) hvor man kan finne og booke underholdning på en enkel måte. Vi tilbyr artister, DJs, komikere, foredragsholdere, dansere, kokker og annen underholdning som passer til ulike typer arrangementer. I 2022 er målet å etablere seg i Norge før vi skal skalere videre til nye markeder.Vi har en stor profilbase, samt gode og etablerte partnerskap med flere av Norges største eventbyråer og bedrifter.

Bytt.no er Norges største sammenligningstjeneste for tjenester og produkter innen personlig økonomi. Hver dag bruker tusenvis av nordmenn Bytt.no for å lese verifiserte brukeromtaler om selskaper og sammenligne priser på tusenvis av tjenester og produkter. Vi er en rendyrket IT-bedrift innen fintech og insurtech som digger å løse problemer ved hjelp av ny teknologi. Vårt primære mål er å koble nye kunder med gode bedrifter. Vi jobber med å forenkle, tilgjengeliggjøre og sammenligne tradisjonelt gammeldagse og lite transparente bransjer ved hjelp av teknologi og smarte løsninger. Lyst til å jobbe med oss? Vi har ledige stillinger, sjekk: www.bytt.no/jobb

Exabel is an artificial intelligence startup based in Oslo, Norway. Exabel’s mission is to synthesize the world’s information and learn how it evolves. We are developing a smart digital assistant software tool for professional investment managers. We are currently a team of 6 full-time employees, with diverse backgrounds; two mathematicians, three software engineers, and a business developer. Combined, we have strong experience with companies like Google, Medallia, Arctic Securities, Intelligent Trading, Microsoft, and Brain Corporation. We are located in Forskningsparken, by StartupLab. The company is well funded for several years of research, product development, and market launch.

For SMB, who wants to create a carbon inventory and budget, the Scope321 platform is a carbon reporting tool, that is easy to use, automates data gathering and integrates with suppliers. Unlike current carbon reporting systems, our product will translate your accounting data into carbon data, so you don't have to track it in other systems or logs.

Adams Matkasse gjør god mat enkel, og samler familien rundt middagsbordet. Landslagskokk og matkreatør i Adams Matkasse, Adam Bjerck, er stadig på reise rundt om i Norge og Europa for å finne frem til de beste råvarene. Sammen med sitt menyteam, bestående av kokker og ernæringsfysiolog, komponerer Adam ukentlige menyer, som sammen med ferske råvarer blir levert rett hjem på døren til over 10 000 familier rundt om i hele Norge. Matkassene består av norsk fisk og kjøtt, sesongens grønnsaker og inspirasjon fra hele verden. Å inspirere familier til å spise god og sunn mat, og spare tid der det trengs mest – det er tanken bak Adams Matkasse.